MedPath

Impact of Flaxseed on the Syndrome Metabolic Inflammation

Not Applicable
Completed
Conditions
Metabolic Syndrome
Interventions
Other: Flaxseed or rice raw powder ingestion
Registration Number
NCT02132728
Lead Sponsor
University of Sao Paulo
Brief Summary

This study aims to evaluate the effects of enterolignanas of flaxseed on nutritional and inflammatory indicators in male workers of a food industry.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
52
Inclusion Criteria
  • Work in the manufacturing company in the city of Itu-SP.
  • Have at least three of the following cardiovascular risk factors: waist circumference ≥ 90 cm; overweight or obese characterized by BMI ≥ 25 kg/m²; fasting total cholesterol ≥ 200 mg/dL, LDL- cholesterol ≥ 130 mg/dL and HDL-cholesterol < 40 mg/dL, triglycerides ≥ 150 mg/dL; glycemia ≥100 mg/dL; and hypertension characterized by systolic blood pressure ≥140 mm/Hg and/or diastolic blood pressure ≥ 90 mm/Hg.
Read More
Exclusion Criteria
  • Female gender
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Flaxssed and low carb groupFlaxseed or rice raw powder ingestionIn this group with 14 volunteers, they received 32% carbohydrate, 47% fat, 21% protein and 60 g of flaxseed powder / day during the period of study.
Flaxseed groupFlaxseed or rice raw powder ingestionIn this group with 14 volunteers, they received 50% carbohydrate, 31% fat, 19% protein and 60 g of flaxseed powder / day during the period of study.
Rice and low carb groupFlaxseed or rice raw powder ingestionIn this group with 13 volunteers, they received 35% carbohydrate, 46% fat, 19% protein and 60g of raw rice powder / day during the period of study.
Primary Outcome Measures
NameTimeMethod
Inflammatory markers and hormones blood levelsAfter 12-hour fast, in the first and 42th day of intervention

For detection of insulin by chemiluminescence, we used the IMMULITE 1000® SYSTEMS - SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS (SIEMENS) (Los Angeles, USA).

The determination of ultra-sensitive CRP (C-reactive protein) by immunoturbidimetric assay was performed with the COBAS® MIRAPLUS - ROCHE (USA). The Tumor Necrosis Factor (TNF-α), leptin, and adiponectin were measured by enzyme immunoassay method, using kits of LINCOPLEX-LUMINEX®, manufactured by Millipore Corporation (USA). Determination of 8-Iso-Prostaglandin F2a (serum isoprostane) was performed by enzyme immunoassay with ASSAYS® DESIGNS kit, Inco, USA.

Secondary Outcome Measures
NameTimeMethod
Blood lipid profileAfter 12-hour fast, in the first and 42th day of intervention

The determination of total cholesterol, high density lipoprotein (HDL-c), triglyceride, glucose and uric acid was performed by enzymatic method, with HITACHI® 912 - ROCHE (Japan). The reagent used for measurement of total cholesterol and triglyceride was CHOD-PAP, ROCHE (Japan); for HDL-c: Bioclin K071 (Japan); for glucose: GOD-PAD (Roche) (Japan); and for uric acid was Uric Acid Plus (URICASE) (Japan). To determine the values of low density lipoprotein (LDL-c) the Friedewald Formula was used.

Trial Locations

Locations (1)

Clinical Hospital of Ribeirao Preto

🇧🇷

Ribeirão Preto, São Paulo, Brazil

© Copyright 2025. All Rights Reserved by MedPath